Impact of β-blocker selectivity on long-term outcomes in congestive heart failure patients with chronic obstructive pulmonary disease
about
Effect of beta-blockers on exacerbation rate and lung function in chronic obstructive pulmonary disease (COPD).Underuse of β-blockers in heart failure and chronic obstructive pulmonary disease.The safety and tolerability of beta blockers in heart failure with reduced ejection fraction: is the current underutilization of this evidence-based therapy justified?Management of Chronic Obstructive Pulmonary Disease in Patients with Cardiovascular Diseases.Chronic Obstructive Pulmonary Disease and Cardiac Diseases. An Urgent Need for Integrated Care.The Real Role of β-Blockers in Daily Cardiovascular Therapy.Pharmacological Management of Elderly Patients with Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome: Room for Speculation?Association of asthma-chronic obstructive pulmonary disease overlap syndrome with coronary artery disease, cardiac dysrhythmia and heart failure: a population-based retrospective cohort study.Paradigms in chronic obstructive pulmonary disease: phenotypes, immunobiology, and therapy with a focus on vascular disease.An old debate still in the β-phase?Therapeutic effects of the combination of inhaled beta2-agonists and beta-blockers in COPD patients with cardiovascular disease.What constitutes optimal neurohumoral antagonism in chronic heart failure?Relationship between heart failure, concurrent chronic obstructive pulmonary disease and beta-blocker use: a Danish nationwide cohort study.Chronic obstructive pulmonary disease and β-blocker treatment in Asian patients with heart failure.Comparison of Long-Term Clinical Implications of Beta-Blockade in Patients With Obstructive Airway Diseases Exposed to Beta-Blockers With Different β1-Adrenoreceptor Selectivity: An Italian Population-Based Cohort Study
P2860
Q33814586-DDB65FBA-5073-4361-9C82-753768F4D77DQ37471531-282EC64D-7E68-446E-88FA-1F8455C0166CQ38613058-0F9D7096-4006-4168-BC3B-75CA416E3EB1Q38871993-31FDD033-125B-4B53-8C42-348EF64BB172Q38944856-26BEFA1A-7E90-4948-8FE5-F7067F9C39CBQ39208428-746BEBAD-1675-4F71-8045-AD075F0CC454Q40771974-888657E2-8777-4499-AEFA-D100F1632F3DQ42376769-6088015A-621A-4F57-9271-A6ECCAB833A6Q46165199-86673DAD-F68C-4943-98FD-C9B9740BE2DFQ47658450-F69C6E6A-21E1-49B8-8FD8-C93F68F5B34BQ47792766-34D62219-A305-44E7-A14B-37D42893B388Q47814853-094AF2BF-7A11-49B6-81B2-5E7C7A0CC0D3Q49841575-E7890EED-ABAE-4C14-8C7C-66CF3FFBBEE4Q50064555-75A8E6E0-8C59-40EE-9EB6-54AED1C298C1Q59136323-45091290-3B50-4465-BB08-2A3C7A0E3B16
P2860
Impact of β-blocker selectivity on long-term outcomes in congestive heart failure patients with chronic obstructive pulmonary disease
description
2015 nî lūn-bûn
@nan
2015 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի մարտին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Impact of β-blocker selectivit ...... obstructive pulmonary disease
@ast
Impact of β-blocker selectivit ...... obstructive pulmonary disease
@en
type
label
Impact of β-blocker selectivit ...... obstructive pulmonary disease
@ast
Impact of β-blocker selectivit ...... obstructive pulmonary disease
@en
prefLabel
Impact of β-blocker selectivit ...... obstructive pulmonary disease
@ast
Impact of β-blocker selectivit ...... obstructive pulmonary disease
@en
P2093
P2860
P356
P1476
Impact of β-blocker selectivit ...... obstructive pulmonary disease
@en
P2093
Erito Furuse
Koji Murai
Kuniya Asai
Shunichi Nakamura
Wataru Shimizu
Yayoi Tetsuou Tsukada
Yoshiaki Kubota
P2860
P304
P356
10.2147/COPD.S79942
P407
P577
2015-03-05T00:00:00Z